key: cord-0735776-d1him0tj authors: Marschner, Constantin A.; Shaw, Kirsten E.; Tijmes, Felipe Sanchez; Fronza, Matteo; Khullar, Sharmila; Seidman, Michael A.; Thavendiranathan, Paaladinesh; Udell, Jacob A.; Wald, Rachel M.; Hanneman, Kate title: Myocarditis Following COVID-19 Vaccination date: 2022-05-06 journal: Cardiol Clin DOI: 10.1016/j.ccl.2022.05.002 sha: 697ab8bd411f1f71c8b53b2728e9e97c7d9fdf1b doc_id: 735776 cord_uid: d1him0tj Myocarditis is an established but rare adverse event following administration of messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines, and is most common in male adolescents and young adults. Symptoms typically develop within a few days of vaccine administration. Most patients have mild abnormalities on cardiac imaging with rapid clinical improvement with standard treatment. However, longer term follow-up is needed to determine whether imaging abnormalities persist, to evaluate for adverse outcomes, and to understand the risk associated with subsequent vaccination. The purpose of the review is to evaluate the current literature related to myocarditis following COVID-19 vaccination, including the incidence, risk factors, clinical course, imaging findings and proposed pathophysiologic mechanisms. Following the discovery of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in December 2019, there has been intense focus on the development of vaccines to limit the contagion and severity of coronavirus disease 2019 . On December 11, 2020 Several side effects have been reported after administration of COVID-19 vaccines, the majority of which are mild and self-limited. These include pain at the injection site, lymphadenopathy ipsilateral to the site of injection, fever, chills, myalgias, headache and fatigue (1) . Serious side effects have been reported in a very small proportion of individuals following COVID-19 vaccination. These include thrombosis with thrombocytopenia syndrome (TTS) following administration of viral vector vaccines and myocarditis and pericarditis following administration of mRNA-based vaccines (2) (3) (4) . Myocarditis is an inflammatory disease of the myocardium without an ischemic cause, which can be diagnosed by histological, immunological and imaging criteria (5) . Pericarditis refers to non-ischemic inflammation of the pericardium. The term myopericarditis is used when both the myocardium and pericardium are inflamed. Myocarditis following vaccination had been described very rarely prior to the introduction of COVID-19 vaccines, including following smallpox and anthrax vaccines (6) . Although rare, there has been intense interest in myocarditis following COVID-19 vaccination, particularly given the higher incidence of this adverse event in young men and concerns about the potential for long-term sequelae. The purpose of the review is to evaluate the current literature related to myocarditis following COVID-19 vaccination, including the incidence, risk factors, clinical presentation, imaging findings, proposed pathophysiologic mechanisms, treatment and prognosis. There is no test or investigation that can establish causality for vaccine associated myocarditis or pericarditis. These associations are based on a close temporal relationship between vaccine administration and the onset of symptoms, usually defined as within 14 days although ranges of up to a month have been reported in the literature (7) (8) (9) (10) . The U.S. Centers of Disease Control and Prevention (CDC) has established case definitions of acute myocarditis and pericarditis, including probable or confirmed acute myocarditis and probable acute pericarditis, summarized in Table 1 (3). In the United States, most of the data on the incidence of adverse events following vaccination has been gleaned from the Vaccine Adverse Events Reporting System (VAERS). As of January 7, 2022, VAERS had received 2,478 reports of myocarditis and 1,900 reports of pericarditis following COVID-19 vaccination (11) . Of note, the VAERS is a passive adverse event reporting system with limitations including reporting bias. Post-vaccine myocarditis has been documented worldwide, with no clear identified pattern of increased prevalence based on geographic region. Reported rates from different healthcare organizations across the world are similar, including large population-based studies from Israel and California (12, 13) . A recent systematic review estimated that the overall incidence of myopericarditis following COVID-19 vaccination is 18 per million vaccine doses (14) . Compared with COVID-19 vaccines, the incidence of myopericarditis was higher following vaccination for small pox (132 per million vaccine doses) and did not differ significantly with the incidence of myopericarditis following influenza vaccination (1.3 per million vaccine dose) or other non-small pox vaccination (57 per million vaccine doses) (14) . The risk of myocarditis associated with mRNA-based COVID-19 vaccination is highest in males between 12 and 29 years of age following administration of the second dose (8, 12, 13, 15, 16) . As of June 2021, crude reporting rates of myocarditis following COVID-19 vaccination based on VAERS data were 40.6 cases per million second doses among males aged 12-29 years and 4.2 cases per million second doses among females aged 12-29 years (17). The striking sex difference in adolescents and young adults has led to proposed pathophysiologic mechanisms related to sex hormones and has raised questions about the potential for under-diagnosis of myocarditis in women compared to men (8) . Rates of myocarditis following COVID-19 vaccination are much lower in younger children between 5 and 11 years of age and adults over 30 years of age (17). As of December 19, 2021, reported rates of myocarditis based on VAERS data per 1 million doses of Pfizer-BioNTech COVID-19 vaccines administered were only 4 for males aged 5-11 years compared to 46 for males aged 12-15 years and 70 for males aged 16-17 years after the second dose. For females, rates were 2, 4, and 8 in the same age ranges, respectively (18) . The vaccine formulation of the Pfizer mRNA vaccine for ages 5-11 years of age is one third the dose of the formulation for those aged 12 years and older, which raises the possibility of a weight-based dose response relationship in younger adolescents who have lower body weight compared to adults. Among mRNA-based COVID-19 vaccines, myocarditis is more common following the Moderna vaccine compared to the Pfizer-BioNTech COVID-19 vaccine, although absolute cases numbers vary depending on local availability of each vaccine (7, 19) . A study of more than 2.5 million people who received the Pfizer-BioNTech COVID-19 vaccine demonstrated an estimated incidence of myocarditis of 2.1 cases per 100,000 persons (13) , while a study of nearly 500,000 people vaccinated with the Moderna vaccine demonstrated an incidence of 4.2 cases per 100,000 persons (7) . A large J o u r n a l P r e -p r o o f population-based study in Denmark found that the rates of myocarditis among individuals aged 12-39 years were 1.6 per 100,000 individuals for Pfizer-BioNTech and 5.7 per 100,000 individuals for Moderna (7) . Myocarditis is much more common following the second dose compared to the first, but has also been reported following the first dose particularly in those with a prior history of COVID-19 infection (4). There are limited data on the risk of myocarditis following third and subsequent booster doses (20, 21) . However, the risk after the third dose appears to be lower than following the second dose (14, 22) . History of prior exposure is likely relevant as well as shorter interval between doses (23). There are a few case reports of recurrent myocarditis following administration of mRNA-based COVID-19 vaccines (24, 25). However, the risk of recurrence of myocarditis following receipt of additional doses of mRNA COVID-19 vaccines in individuals with a history of confirmed myocarditis is currently unknown (26). One pre-print article suggests that the risk of myocarditis among individuals who received the Moderna vaccine for the second dose was higher for those who had a heterologous as opposed to homologous vaccine schedule (i.e. higher in those who had received a COVID-19 vaccine other than the Moderna vaccine for their first dose) (23). Infection with SARS-CoV-2 can also result in myocardial inflammation, which is associated with adverse outcomes in hospitalized patients, and should be balanced against the risk of vaccine-related complications (27) . Overall, the rates of myocarditis following SARS-CoV-2 infection are much higher than after vaccination (17). Data from the largest integrated health care organization in Israel indicate that SARS-CoV-2 infection is associated with an excess risk of myocarditis when compared to age and risk-matched controls (risk ratio 18.3 and risk difference 11.0 events per 100,000 persons) that is much higher than the excess risk of myocarditis following administration of Pfizer-BioNTech COVID-19 vaccine (risk ratio 3.2 and risk difference 2.7 events per 100,000 persons) (28) . Similarly, higher risk of myocarditis after SARS-CoV-2 infection compared to COVID-19 vaccination was recently demonstrated in a study in England that evaluated over 38 million individuals aged  16 J o u r n a l P r e -p r o o f years who had received at least one dose of a COVID-19 vaccine (9). The extent of abnormalities on cardiac magnetic resonance imaging (CMR) are also less severe in myocarditis following COVID-19 vaccination compared to myocarditis following SARS-CoV-2 infection (29). The clinical presentation of myocarditis following COVID-19 vaccination is similar to that of myocarditis due to other causes (Table 1 ). Chest pain is the most frequently reported presenting symptom (19, (30) (31) (32) . However, as with myocarditis from other causes, myocarditis following COVID-19 vaccination can present with variable symptoms ranging from subclinical presentations to acute arrythmia, heart failure or rarely cardiogenic shock (3, 13, 19) . Most patients with myocarditis following COVID-19 vaccination demonstrate symptom onset within the first week after vaccination, with the vast majority presenting within the first 4 days (19, (33) (34) (35) . This is similar to myocarditis following non-COVID vaccination where symptom onset is usually less than two weeks after vaccine administration (11, 12) . Histopathology Endomyocardial biopsy is not frequently performed in the setting of acute myocarditis but is indicated in patients with suspected myocarditis when diagnostic confirmation will alter therapy, in cases of hemodynamic instability or with clinical deterioration despite supportive care (36). A negative endomyocardial biopsy does not exclude the diagnosis of myocarditis given sampling imprecision associated with spatial heterogeneity (patchiness) of the disease (3, 36-38). However, it should also be noted that cardiac dysfunction mimicking myocarditis may result from a systemic increase in cytokine production, which does not have a histological correlate (37, 39-41). There are very few reports of histologically documented myocarditis following COVID-19 vaccination in the literature to date. Lymphocytic myocarditis is the predominant pattern observed in biopsied and autopsied hearts and occurs most frequently in adolescents and young adult males who present with mild, self-limited disease (3, (41) (42) (43) . In rare instances it may manifest as a fulminant, potentially fatal disease with no sex predilection (44) (45) (46) . Depending upon the timing of histological assessment, a pattern of healing myocarditis may be present. Ameratunga A summary of diagnostic test findings in acute myocarditis is provided in Table 2 . Cardiac imaging plays an important role in establishing a diagnosis of myocarditis and pericarditis, excluding other potential causes of symptoms, and risk-stratifying patients. Transthoracic echocardiography is often the first cardiac imaging modality performed in the setting of suspected myocarditis, allowing for assessment of cardiac size and function and associated findings including the presence of a pericardial effusion. Although most findings in the setting of myocarditis are not specific, focal echogenicity, particularly in the lateral and inferior wall, and the presence of pericardial effusions have been shown to be sensitive for acute myopericarditis in young adults (52) . Speckle tracking based myocardial strain is also a potentially sensitive method to identify acute myocarditis with echocardiography (53) . Impaired ventricular function is a predictor of poor outcomes, and echocardiography is also useful in follow-up to ensure recovery of function (54). . T2-based criteria include increased native T2, regional T2-hyperintensity, or increased myocardial T2 signal intensity ratio compared to skeletal muscle on T2-weighted imaging. Regional and global left ventricular dysfunction and findings associated with pericarditis (including presence of a pericardial effusion and pericardial enhancement) are supportive criteria but are not required. Although the presence of both T1-and T2-based criteria is associated with the highest specificity for active myocardial inflammation, the presence of only one criterion could still be consistent with a diagnosis of myocarditis, particularly if imaging was delayed after symptom onset or performed after immunosuppressive treatment is started (in which case edema might no longer be detectable) (4) . Given the importance of establishing a diagnosis of myocarditis, CMR should ideally be performed as soon as possible after the onset of symptoms. This may be particularly relevant in the setting of myocarditis following COVID-19 vaccination given reports of very rapid resolution of symptoms and the potential implications of a diagnosis on recommendations for future vaccination (4). In acute myocarditis in general, LGE most commonly occurs in a subepicardial pattern and is often located at the basal inferior lateral wall. Mid-wall and septal patterns of LGE are less common but are associated with a worse prognosis (62) . Myocardial edema is usually focal, however diffuse changes have also been described (63) . In the acute setting, LGE co-localizing with edema is often associated with functional recovery as edema improves over time (64) . However, isolated LGE without edema often reflects fibrosis, which is a risk-marker for major cardiac events including sudden cardiac death and heart failure (64) . Native T1, T2 and ECV allow for quantification of myocardial tissue changes and are all elevated in the setting of myocardial edema. On the other hand, elevation of T1 and ECV in the setting of normal T2 values are suggestive of healed myocarditis with fibrosis but no active edema (4). The pattern of CMR findings in myocarditis following COVID-19 vaccination is similar to myocarditis due to other causes, although the extent and severity of abnormalities tends to be milder (4) . Typical findings in the acute phase include subepicardial LGE and co-localizing edema at the basal to mid inferolateral wall, Figure 3 . Compared with other causes of myocarditis, patients with vaccine associated myocarditis have higher left ventricular ejection fraction, less extensive LGE, and less frequent involvement of the septum (29). Follow-up CMR is often performed 3-6 months after acute myocarditis to evaluate for recovery of left ventricular function, resolution of edema, and any residual scarring, although there are no established guidelines defining the optimal timing of follow-up imaging (65) . There is limited follow-up CMR data in myocarditis following vaccination (66) (67) (68) (69) . In a case series of 13 adults with acute myocarditis Other diagnostic investigations used frequently in the setting of myocarditis and pericarditis include electrocardiography (ECG) and assessment of cardiac blood biomarkers. ECG findings in myocarditis are non-specific but can include ST-segment elevation, T-wave inversions, and ectopic beats (31, 34, 70) . While these findings have low sensitivity for myocarditis, ECG is frequently used in patients with suspected myocarditis to evaluate for alternative causes of cardiac symptoms (70) . In the setting of pericarditis, typical ECG changes include concave upward ST-segment elevation, upright T waves in the leads with ST-segment elevation, and PR depression. ECG findings in the setting of myocarditis and pericarditis following COVID-19 vaccination are similar to other causes (19, 70) . Although not specific to myocarditis, elevated troponin levels, indicating myocyte injury, are almost always present in the setting of acute myocarditis (3, 19, 30, 71) . The degree of troponin elevation varies and is dependent on the severity of myocardial injury and timing of evaluation in relation to Currently, there are no specific management recommendations for myocarditis following COVID-19 vaccination. Care is largely supportive following guidelines for myocarditis due to other causes (39). Treatment is typically focused on addressing potential sequelae such as heart failure or arrhythmia as per guideline-directed medical therapy. For patients with very mild symptoms with rapid improvement, therapy can often be deferred. Individuals are typically safe to return to their normal daily activities after their symptoms improve. However, the optimal duration of exercise restriction is unknown. The American Heart Association and American College of Cardiology Foundation have recommended 3-6 months of restriction from competitive sports following myocarditis. Repeat evaluation of serum biomarkers, 24-hour Holter monitor, and echocardiography are recommended prior to return to exercise in order to ensure normal ventricular function, resolution of active inflammation, and absence of arrhythmias (72) . Although there is no clear evidence on risk associated with subsequent vaccination, current guidelines suggest that further doses of mRNA COVID-19 vaccines should be deferred among individuals who experienced myocarditis within 6 weeks of receiving a previous dose of an mRNA COVID-19 vaccine (26). Myocarditis following COVID-19 vaccination is typically associated with a transient, mild course, with complete resolution of symptoms within 1-3 weeks in the vast majority of patients (3, 19, 30, 34) . Patients with more severe disease with ventricular dysfunction might require hospitalization, although most reports indicate that patients who do require hospitalization typically require a short J o u r n a l P r e -p r o o f stay of less than 5 days (19, 34) . Patients rarely require intensive care unit admission or re-admission following hospital discharge (12) . Although most patients with myocarditis after COVID-19 vaccination have a mild course, there are limited long-term follow-up data given the relatively recent introduction of these vaccines. Improvement or normalization of ejection fraction and resolution of symptoms in nearly all patients with myocarditis following COVID-19 vaccination has been demonstrated at short-interval follow-up (12) . Limited intermediate term (~5-6 months) follow-up data has demonstrated normalization of troponin levels, no residual cardiac symptoms or functional impairment, and no adverse cardiac events (66, 68) . Although these data are reassuring, further studies with long-term clinical and imaging follow-up are needed. Additional study is also needed to determine the risk with subsequent vaccine doses and other potential risk factors including prior history of myocarditis. Myocarditis is an established but rare adverse event following administration of mRNA-based COVID-19 vaccines, most commonly diagnosed in male adolescents and young adults. Symptoms typically develop within a few days of vaccine administration. Most patients have mild abnormalities on cardiac imaging with rapid clinical improvement with standard treatment, which is reassuring. However, longer term follow-up is needed to determine whether imaging abnormalities persist, to evaluate for adverse outcomes, and to understand the risk associated with subsequent vaccination. • Myocarditis following mRNA-based COVID-19 vaccines is rare; however, adolescent and young adult males are at highest risk. • Chest pain is the most common symptom, with typical onset within a few days of vaccine administration. • CMR plays an important role in the diagnosis of acute myocarditis following vaccination, with typical findings of subepicardial late gadolinium enhancement and co-localizing edema at the basal inferior lateral wall. • The disease course of myocarditis following COVID-19 vaccination is typically transient and mild, with resolution of symptoms within 1-3 weeks in most patients. • However, longer term follow-up is needed to determine whether imaging abnormalities persist, to evaluate for adverse outcomes, and to understand the risk associated with subsequent vaccination. Evolution of Lymphadenopathy at PET/MRI after COVID-19 Vaccination US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination Myocarditis With COVID-19 mRNA Vaccines Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS) SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination Public Health Service (PHS), Centers for Disease Control (CDC) / Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS) Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older Myocarditis after Covid-19 Vaccination in a Large Health Care Organization Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and metaanalysis Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices -United States COVID-19 vaccine safety updates: Primary series in children and adolescents ages 5-11 and 12-15 years, and booster doses in adolescents ages 16-24 years 2022 Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military Myocarditis Associated With COVID-19 Booster Vaccination Imaging of Myocarditis Following mRNA COVID-19 Booster Vaccination Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent Summary of NACI advice on vaccination with COVID-19 vaccines following myocarditis (with or without pericarditis Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting Myocardial injury pattern by MRI in COVID-19 Vaccine Associated Myocarditis A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel COVID-19 Vaccination-Associated Myocarditis in Adolescents Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation Myocarditis after Covid-19 mRNA Vaccination First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity Reaction Post RNA-based COVID vaccines myocarditis: Proposed mechanisms The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism Clinical evaluation of myocardial involvement in acute myopericarditis in young adults Speckle tracking echocardiography in acute myocarditis Comparison between myocardial function assessed by echocardiography during hospitalization for COVID-19 and at 4 months follow-up Usefulness of Late Iodine Enhancement on Spectral CT in Acute Myocarditis The role of positron emission tomography in the assessment of cardiac sarcoidosis Combined Cardiac Fluorodeoxyglucose-Positron Emission Tomography/Magnetic Resonance Imaging Assessment of Myocardial Injury in Patients Who Recently Recovered From COVID-19 Assessment of Myocarditis: Cardiac MR, PET/CT, or PET/MR? Curr Initial Experience With Simultaneous 18F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis Myocardial Inflammation in COVID-19 Associated Myocarditis Detected by Multiparametric Cardiac Magnetic Resonance Imaging Prognostic Value of Repeating Cardiac Magnetic Resonance in Patients With Acute Myocarditis Myocarditis and inflammatory cardiomyopathy: current evidence and future directions MRI and Clinical Follow-Up in COVID-19 Vaccine Associated Myocarditis Persistent Cardiac MRI Findings in a Cohort of Adolescents with post COVID-19 mRNA vaccine myopericarditis Patients With Myocarditis Associated With COVID-19 Vaccination Cardiac Magnetic Resonance Imaging Midterm Follow Up of COVID-19 Vaccine-Associated Myocarditis Update on myocarditis Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the